Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Kittel, Anja ^a   Müller, Fabian ^a   König, Jörg ^a   Mieth, Maren ^a   Sticht, Heinrich ^a   Zolk, Oliver ^a,b   Kralj, Ana ^a   Heinrich, Markus R ^a   Fromm, Martin F ^a   Maas, Renke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 METHYLPROPIONIC ACID; 6 N,N' DIMETHYLARGININE; CREATININE; N(G),N(G) DIMETHYLARGININE; 2 AMINO 2 METHYLPROPIONIC ACID; 3-AMINOISOBUTYRIC ACID; ALANINE-GLYOXYLATE TRANSAMINASE; AMINOTRANSFERASE; ARGININE; DIMETHYLARGININE;

ADULT; AGXT2 GENE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINO ACID URINE LEVEL; AMINOACIDURIA; ARTICLE; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; ENZYME ACTIVITY; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; FEMALE; GENE; HAPLOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CELL; MALE; NORMAL HUMAN; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; CELL LINE; GENETICS; HEK293 CELL LINE; METABOLISM; URINE; YOUNG ADULT;

ADULT; AMINOISOBUTYRIC ACIDS; ARGININE; CELL LINE; FEMALE; HAPLOTYPES; HEALTHY VOLUNTEERS; HEK293 CELLS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSAMINASES; YOUNG ADULT;

EID: 84896124147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088544     Document Type: Article

References (38)

1. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, et al. (2011) Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 57: 112-121.
2. Böger RH, Maas R, Schulze F, Schwedhelm E (2009) Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Int J Clin Pharmacol Res 60: 481-487.
3. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97: e53-59.
4. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, et al. (2007) Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13: 198-203.
5. Jacobi J, Maas R, Cordasic N, Koch K, Schmieder RE, et al. (2008) Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 294: H1058-1066. (Pubitemid 351253320)
6. Strobel J, Mieth M, Endreß B, Auge D, König J, et al. (2012) Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol 53: 392-400.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575.
8. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, et al. (2007) Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282: 879-887. (Pubitemid 47076535)
9. Maas R, Böger R, Lüneburg N (2009) ADMA and the role of the genes: lessons from genetically modified animals and human gene polymorphisms. Pharmacol Res 60: 475-480.
10. Kontani Y, Kaneko M, Kikugawa M, Fujimoto S, Tamaki N (1993) Identity of D-3-aminoisobutyrate-pyruvate aminotransferase with alanine-glyoxylate aminotransferase 2. Biochim Biophys Acta 1156: 161-166. (Pubitemid 23049949)
11. Wang S, Hu CP, Yuan Q, Zhang WF, Zhou Z, et al. (2012) Dimethylarginine dimethylaminohydrolase 1 regulates nerve growth factor-promoted differentiation of PC12 cells in a nitric oxide-dependent but asymmetric dimethylargenine- independent manner. J Neurosci Res 90: 1209-1217.
12. G- dimethylarginine in rats. Arch Biochem Biophys 252: 526-537.
13. Lüneburg N, Lieb W, Schwedhelm E, Zeller T, Carter A, et al. (2011) Genome-wide association study of dimethylarginines reveals novel metabolic pathway for SDMA (Abstract). Circulation 1 24: A1 2560.
14. Caplin B, Wang Z, Slaviero A, Tomlinson J, Dowsett L, et al. (2012) Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure. Arterioscler Thromb Vasc Biol 32: 2892-2900.
15. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, et al. (2011) A genome-wide association study of metabolic traits in human urine. Nat Genet 43: 565-569.
16. Crumpler HR, Dent CE, Harris H, Westall RG (1951) b-Aminoisobutyric acid (α-methyl-β-alanine); a new amino-acid obtained from human urine. Nature 167: 307-308.
17. Schmidt C, Hofmann U, Kohlmuller D, Murdter T, Zanger UM, et al. (2005) Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry. J Inherit Metab Dis 28: 1109-1122. (Pubitemid 43168948)
18. Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E (2011) Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2294-2298.
19. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, et al. (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851: 211-219. (Pubitemid 46720141)
20. Kittel A, Maas R, König J, Mieth M, Weiss N, et al. (2013) In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice. Biochem Biophys Res Commun 430: 84-89.
21. Malashkevich VN, Strop P, Keller JW, Jansonius JN, Toney MD (1999) Crystal structures of dialkylglycine decarboxylase inhibitor complexes. J Mol Biol 294: 193-200.
22. Sanchez R, Sali A (2000) Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol 143: 97-129.
23. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723. (Pubitemid 28059943)
24. Hooft RW, Vriend G, Sander C, Abola EE (1996) Errors in protein structures. Nature 381: 272.
25. Sayle RA, Milner-White EJ (1995) RASMOL: biomolecular graphics for all. Trends Biochem Sci 20: 374.
26. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR (2010) Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 285: 5385-5391.
27. Lüneburg N, Lieb W, Bernges I, Kittel A, Zeller T, et al. (2011) Genome-wide association study reveals novel metabolic pathway for SDMA (Abstract). Br J Clin Pharmacol 72: 42-42.
28. Nicholson G, Rantalainen M, Li JV, Maher AD, Malmodin D, et al. (2011) A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet 7: e1002270.
29. Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, et al. (2013) A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab 18: 130-143.
30. Blumberg BS, Gartler SM (1959) High prevalence of high-level β-amino-isobutyric acid excretors in Micronesians. Nature 184: 1990-1992.
31. De Grouchy J, Sutton HE (1957) A genetic study of β-aminoisobutyric acid excretion. Am J Hum Genet 9: 76-80.
32. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D (2006) Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 21: 2446-2451. (Pubitemid 44644516)
33. Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Atzler D, et al. (2011) Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med 49: 1907-1910.
34. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, et al. (2010) Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208: 518-523.
35. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, et al. (2013) Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102: 193-202.
36. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R (2009) Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 24: 1429-1435.
37. SeppäläI, Kleber ME, Lyytikäinen LP, Hernesniemi JA, Mäkelä KM, et al. (2013) Genome-wide association study on dimethylarginines reveals novel AGXT2 variants associated with heart rate variability but not with overall mortality. Eur Heart J.
38. Kleber M, SeppäläI, Pilz S, Hoffmann A, Tomaschitz N, et al. (2013) Genome-wide association study identifies three genomic loci significantly associated with serum levels of homoarginine - The AtheroRemo Consortium. Clin Res Cardiol 102 Suppl 1: V944.